FDMT — 4D Molecular Therapeutics Share News
0.000.00%
Last trade - 00:00- $710.99m
- $369.25m
- $85.21m
U.S. RESEARCH ROUNDUP-Penn Entertainment, Roblox, Sonendo
4D Molecular Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Brief: 4D Molecular Therapeutics Inc Files For Mixed Shelf Of Up To $300 Million - SEC Filing
Brief: 4D Molecular Therapeutics Q2 Revenue USD 239 Thousand Vs. IBES Estimate USD 848.3 Thousand
4D Molecular Therapeutics Inc expected to post a loss of 81 cents a share - Earnings Preview
Brief: 4DMT Presents Additional Positive Interim Data From Intravitreal 4D-150 Phase 1/2 PRISM Clinical Trial In Patients With Wet AMD At ASRS 2023
Brief: 4DMT Completes Enrollment Of Phase 2 Prism Clinical Trial For Intravitreal 4D-150 In Patients With Wet AMD And Reports Interim Safety And Tolerability Data
Brief: Astellas Says Co And 4D Molecular Therapeutics (4DMT) Have Entered Into License Agreement To Use 4DMT's Proprietary Intravitreal R100 Vector For Rare Ophthalmic Targets
U.S. STOCKS ON THE MOVE-Constellation Energy, Cactus, Cardinal Health
U.S. STOCKS ON THE MOVE-CureVac, Aclarion, Baosheng Media
U.S. STOCKS ON THE MOVE-Carvana, Annovis Bio, Aclarion
U.S. STOCKS ON THE MOVE-Adobe, Lucid, REV Group
4D Molecular Therapeutics up on positive data in lung disease drug study
Brief: RA Capital Management Reports 6.7% Passive Stake In 4D Molecular Therapeutics
4D Molecular Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
Brief: 4D Molecular Therapeutics Q1 net loss USD 28.682 million
4D Molecular Therapeutics Inc expected to post a loss of 90 cents a share - Earnings Preview
Brief: 4D Molecular Therapeutics Announces Pricing Of Upsized Public Offering Of Common Stock
Brief: 4D Molecular Therapeutics Announces Proposed Public Offering Of Common Stock